| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 7.55▼ | 7.55▼ | 7.56▼ | 7.49▼ | 7.52▼ |
| MA10 | 7.55▼ | 7.56▼ | 7.52▼ | 7.55▼ | 7.60▼ |
| MA20 | 7.41▲ | 7.51▼ | 7.52▼ | 7.67▼ | N/A |
| MA50 | 7.42▲ | 7.58▼ | 7.66▼ | 7.66▼ | N/A |
| MA100 | 7.75▼ | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.011▲ | 0.015▲ | 0.026▲ | -0.052▼ | N/A |
| RSI | 48.521▼ | 48.213▼ | 48.030▼ | 38.878▼ | N/A |
| STOCH | 31.322 | 63.995 | 69.145 | 27.750 | N/A |
| WILL %R | -62.069 | -29.032 | -29.032 | -93.058▼ | -72.372 |
| CCI | -79.687 | 19.111 | 13.847 | -148.749▼ | -107.695▼ |
|
Thursday, November 06, 2025 05:10 AM
The Health Canada authorization marks an important regulatory milestone in the NS002 development program. This clearance confirms the acceptability of the proposed trial design, supporting safety data ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/11/25 | 7.51 | 7.69 | 7.00 | 7.03 | 2,584 |
| 14/11/25 | 7.75 | 7.75 | 7.40 | 7.41 | 4,401 |
| 13/11/25 | 7.44 | 7.90 | 7.20 | 7.90 | 7,018 |
| 12/11/25 | 6.9278 | 7.62 | 6.9278 | 7.59 | 5,582 |
| 11/11/25 | 7.50 | 7.50 | 7.50 | 7.50 | 0 |
| 10/11/25 | 7.50 | 7.50 | 7.50 | 7.50 | 1,000 |
| 07/11/25 | 7.50 | 7.50 | 7.50 | 7.50 | 849 |
| 06/11/25 | 7.55 | 7.55 | 7.55 | 7.55 | 0 |
| 05/11/25 | 7.5205 | 7.55 | 7.5205 | 7.55 | 3,191 |
| 04/11/25 | 8.00 | 8.00 | 8.00 | 8.00 | 4,364 |
|
|
||||
|
|
||||
|
|